Moxifloxacin: safety profile
The latest, so-called respiratory, fluoroquinolones are a group of antimicrobial agents (AMA), most commonly prescribed for community-acquired lower respiratory tract infection (caLRTI), which is a relevant issue in routine clinical practice.
Auteur principal: | A. I. Sinopalnikov |
---|---|
Format: | Article |
Langue: | Russian |
Publié: |
Remedium Group LLC
2013-12-01
|
Collection: | Медицинский совет |
Sujets: | |
Accès en ligne: | https://www.med-sovet.pro/jour/article/view/1152 |
Documents similaires
-
Community-acquired pneumonia against a background of chronic heart failure: diagnosis and treatment
par: A. A. Bobylev, et autres
Publié: (2014-12-01) -
Moxifloxacin in the treatment of community-acquired pneumonia in adults: what's new?
par: A. I. Sinopalnikov
Publié: (2014-12-01) -
Rational therapy of patients with lower respiratory tract infections
par: V. A. Kazantsev
Publié: (2013-12-01) -
Cough in children as a symptom of respiratory tract infections: a new look at the problem of antibiotic therapy
par: O. A. Egorova
Publié: (2014-12-01) -
Местная иммуномодуляция при заболеваниях верхних дыхательных путей
Publié: (2018-06-01)